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SUMMARY
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hemato-
poietic disorder arising from a mutation in the X chromosome-linked
PIG-A gene. The mutated cell is unable to build the GPI anchor,
which is needed to bind a number of molecules on the outer cell
surface. Some GPI-linked molecules are responsible for cell defense
against activated complement; this is why PNH red cells are hyper-
sensitive to complement attack and are continuously destroyed in the
circulation, with paroxysmal exacerbations. However, many other
defects are present on PNH cell membrane, involving red cells,
granulocytes, monocytes, and platelets, leading to tendency to
infection and thrombosis. This review highlights the molecular
pathophysiology of the disease and analyses the mechanisms
responsible for the expansion of a hematopoietic clone, which is
paradoxically less vital as compared with normal cells.
Key Words: Aplastic anemia; bone marrow failure; CD55/DAF;
CD59/MIRL; clonal hematopoiesis; complement-mediated lysis;
escape theory; GPI anchor; GPI-linked molecules; intravascular
hemolysis; pancytopenia; paroxysmal nocturnal hemoglobinuria;
PIG-A gene; T-cell clonality; thrombophilia.
INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a complex
hematological disorder probably first described three centuries
ago, and regarded as a mystery until the 1980s, when most of its
pathophysiology was elucidated, followed by the 1990s, when the
underlying molecular defect was finally unraveled. The original
denomination, PNH, stresses only one component of the disease
(i.e., a hyperhemolytic state). A more complete updated definition
could read as follows: an acquired blood disorder characterized by
the expansion of one or a few hematopoietic cell clones carrying
a mutation in the X-linked phosphatidylinositol glycan class A
(PIG-A) gene, which renders the cells unable to produce the
glycosyl-phosphatidylinositol (GPI) anchor, against a background
of a reduced bone marrow activity. Some landmarks in the history
of understanding this disorder are listed in Table 86-1. Because of
its complex pathophysiology, the disease has been variously classi-
fied among hemolytic anemias, myelodysplasia, myeloprolifera-
tive disorders or bone marrow failure syndromes; indeed, PNH has
some features of each of these. This chapter reviews advances on
genetic and pathophysiologic issues of PNH, including a summary
of clinical, diagnostic, and therapeutic aspects.
GENETIC BASIS
Although this disease has a well-recognized genetic cause, it is
neither inherited nor transmitted to the progeny. Indeed, it is a
clonal disorder arising from a somatic mutation in the PIG-A gene
of an early hematopoietic progenitor.
THE PIG-A GENE AND THE GPI ANCHOR PIG-A is a
housekeeping gene located on the short arm of the X chromosome
(Xp22.1), the cDNA of which was first isolated in 1993 through
expression cloning and complementation of GPI-deficient cell lines.
The organization of the genomic gene was established by Bessler
in 1994 (Fig. 86-1). This gene encodes for a protein involved in the
synthesis of the GPI anchor, a molecule used by cells to bind a
number of proteins on their own outer surface without a trans-
membrane portion. The functional implications of the GPI anchor-
ing of proteins are not completely understood; they include ease of
assemblage and shedding, lateral mobility, capping, involvement
in endo-, exo-, and potocytosis (a clathrin-independent form of
endocytosis and recycling). There are examples of proteins exist-
ing in both transmembrane and GPI-linked configuration, as a
result of various molecular mechanisms. The adhesion molecule
leukocyte function associated (LFA)-3 (CD58) is encoded by a
gene that may undergo alternative splicing producing two differ-
ent polypeptides, one of which provides the site for GPI-anchor
attachment. Instead, two alternative isoforms of the Fc-γ receptor
III (CD16) result from two different genes expressed in a tissue-
specific fashion (GPI-linked in neutrophils and transmembrane in
natural killer [NK] cells). The strongest evidence that this type of
membrane anchoring is important in cell biology is its high con-
servation among eukaryotic cells; indeed, it is found even in yeast
and trypanosome. The protein encoded by PIG-A, in combination
with at least two other proteins, is essential in the first step of the
complex GPI-anchor biosynthesis pathway, i.e., in the transfer of
N-acetyl glucosamine to phosphatidyl inositol (Fig. 86-2). By
experimental mutagenesis, GPI-deficient cell lines showing
defects in any of the various metabolic steps have been produced;
however, the study of PNH has shown that the same early step is
impaired in all patients, and all patients have a mutation in the
PIG-A gene. The explanation for this finding is that among the
various genes involved in the GPI-anchor synthesis, PIG-A may
be the only one that is X-linked. As a consequence, a single muta-
tion in that gene will produce an abnormal cell in either sex: males
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have only one allele and females have only one functional allele
(as result of X-chromosome inactivation). Although females have
two PIG-A alleles, only half of the mutation will occur in the func-
tional X; thus, the risk of having the disease is the same in both
genders. Because a defect causing a metabolic block is generally
recessive, it is unlikely (although not impossible) that a double
mutation targeting both alleles of an autosomal gene in the same
cell may occur in vivo.
PIG-A MUTATIONS IN PNH Practically all types of muta-
tions have been found in the PIG-A gene of PNH cells: small dele-
tions or insertions producing frameshift, nucleotide substitutions
resulting in stop codon, missense mutations causing amino acids
substitutions or new sites for alternative splicing, large deletions.
Most of the mutations occur in exon 2, probably because it is the
largest; however, no particular clustering of mutations has emerged,
and almost all mutations are unique to each patient (private muta-
tions) (see Fig. 86-1).
Comparing the type of mutations found in PNH with those found
in glucose-6-phosphate dehydrogenase deficiency, another (this time
inherited) X-linked disorder of a housekeeping gene, shows a clear
discrepancy. In PNH, a vast majority of mutations have extremely
severe functional consequences, (i.e., production of truncated pro-
teins), whereas missense mutations are rare; in glucose-6-phosphate
dehydrogenase deficiency almost all mutations are missense, leading
to single amino acid substitutions with conserved (although possibly
altered) function. Two considerations may be relevant to this discrep-
ancy: (1) In hereditary disorders, a complete absence of the product
of a housekeeping gene is probably lethal; thus, only mutations with
residual activity are seen. By contrast, if a mutation is somatically
acquired, it will not affect organ development and, once occurred, it
will affect the genetic make-up of only a small fraction of somatic
cells, which may survive although with some functional abnormality.
(2) If missense mutations in PNH are rare, this means that for a clonal
expansion to take place, the gene must be seriously damaged. Indeed,
the rare missense mutations found in PNH patients are associated
with a marked reduction of GPI-linked proteins, indicating that they
affected mRNA stability or protein function, or both.
MOLECULAR PATHOPHYSIOLOGY
The PIG-A mutation responsible for PNH arises in a multipo-
tent hematopoietic stem cell, which is capable of differentiating
along several lineages; maturation along erythroid, myeloid, and
megakaryocytic lineages is almost always preserved, whereas
lymphoid differentiation (along B- and/or T lineages) is observed
in a minority of patients. As a consequence of the damage of the
GPI-anchor synthesis pathway, all the affected cells in any state of
maturation are deficient in all the GPI-linked molecules, and defi-
ciency is often complete. More than 20 different proteins sharing
the GPI-anchoring system have been described on the surface of
human blood cells (Fig. 86-3). The understanding of their func-
tional significance is limited; in many cases, the study of PNH
patients or cells was an important source of information.
HEMOLYSIS IN PNH PATIENTS Intravascular hemolysis
is the most characteristic clinical feature of PNH; it is because
of increased susceptibility of PNH erythrocytes to complement-
mediated lysis. This abnormality is caused by the absence on
red cell membrane of two complement-regulatory proteins, CD59/
MIRL (membrane inhibitor of reactive lysis) and CD55/DAF (decay
accelerating factor), which are both GPI-linked. This membrane
abnormality renders PNH erythrocytes extremely sensitive to com-
plement activation, which translates in vivo into a hemolytic state
and in vitro into red cell destruction in acified serum (Ham test).
A low level of complement activation is probably a constant phys-
iologic phenomenon, which is greatly amplified during inflamma-
tory or infectious diseases; thus, PNH erythrocytes are chronically
lysed with paroxystic exacerbations. It is unclear why exacerba-
Table 86-1
Landmarks in the History of PNH
Year Scientist Issue
1678 Schmidt First clinical report
1882 Strübing First detailed description
1911 Marchiafava Recognition as disease entity
1937 Ham; Dacie Specific diagnostic test
1956 De Sandre PNH erythrocytes are AchE deficient
1965 Lewis and Dacie PNH granulocytes are NAP-deficient
1966 Rosse and Dacie Two types of PNH erythrocytes
1967 Lewis and Dacie Relation with aplastic anemia
1970 Oni and Luzzatto Evidence of clonal origin
1983 Nicholson-Weller PNH cells are DAF-deficient
1984 Rotoli and Luzzatto In vitro evidence of clonal origin
1986 Medof Relation to GPI-anchoring system
1989 Rotoli and Luzzatto The survival advantage hypothesis
1990 Van der Schoot Cytometry of GPI-deficient cells
1992, 1993 Ueda; Hillmen PNH lymphoblastoid cell lines
1993 Kinoshita Cloning of the PIG-A gene
1994 Bessler and Luzzatto PIG-A gene organization and mutations
1999 Araten PNH cells in normal individuals
2001 Bessler Mouse models
2001, 2002 Karadimitris; Risitano Clonal T-cell expansion in PNH patients
AchE, acetylcholinesterase; DAF, decay accelerating factor (CD55); GPI, glycosyl-phosphatidylinosi-
tol; NAP, neutrophil alkaline phosphatase; PIG-A, phosphatidylinositol glycan class A; PNH, paroxysmal
nocturnal hemoglobinuria.
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Figure 86-1 Phosphatidylinositol glycan class A gene structure and mutations. The genomic gene spans approx 17 kb. Exons (thick blocks,
numbered) and introns (thin lines) are represented in the central bar; untranslated exon regions are in gray. Three mRNA transcripts arising from
alternative splicing were found by Bessler et al., (1994) who also described an unproductive pseudogene mapped to 12q21. Mutations found to
tions occur mainly during the night. In a functional hierarchy,
CD59 plays a major role, as discovered by studying rare inher-
ited conditions in which a single molecule is lacking. A CD59-defi-
cient patient had a PNH-like picture, whereas subjects deficient of
CD55 on red cell membrane (those carrying the rare Inab blood
group phenotype) show no hyperhemolysis. Although CD59 and
CD55 are deficient also on leukocytes, there is no evidence of
reduced leukocyte life-span in PNH patients, probably because
nucleated cells have an additional transmembrane (i.e., non-GPI-
linked) molecule (CD46) that protects them from complement acti-
vation. Sensitivity to complement is the best known, but not the only
defect, of PNH cells. Table 86-2 lists other molecules that are defi-
cient and their specific function, when known.
HEMATOPOIESIS IN PNH PATIENTS A wide spectrum of
clinical picture emerges when several PNH patients are compared
with each other, ranging from almost asymptomatic individuals to
severely ill subjects. Several mechanisms are responsible for such
phenotypic heterogeneity:
1. The coexistence of a variable percentage of normal cells,
which are progeny of residual GPI+ stem cells.
2. A selective destruction of particles succumbing to the acti-
vated complement attack (this is particularly true for PNH
red cells after a paroxysm of hemolysis).
3. The type of molecular lesion in the PIG-A gene, leading
to PNH cells with a variable sensitivity to complement-
mediated lysis (PNH II and PNH III populations).
4. The degree of commitment of the stem cell having the PIG-
A mutation; if the mutation occurs in a totipotent stem cell,
even lymphocytes will carry the PNH defect, whereas a
mutation in a multipotent myeloid cell will not produce
PNH lymphocytes. 
In theory, a mutation in a more committed progenitor could gen-
erate a monolineage PNH; however, patients with a purely myeloid
PIG-A-deficient clone, giving rise to only granulocytes and/or
platelets may remain undetected, as the sparing of the erythroid lin-
eage implies lack of the typical symptoms suggesting PNH.
PNH hematopoiesis is certainly clonal, but clonal does not nec-
essarily mean monoclonal. Initial observations that more than one
abnormal cell population may be present in a single PNH patient
were first inferred by functional studies based on different sensitiv-
ity to complement-mediated lysis and then by flow cytometry in the
early 1990s. The final confirmation of such an unusual pattern came
from DNA analysis, which documented the simultaneous presence
of two or even more different PIG-A mutations in several PNH
patients, each originating a distinct multilineage PNH clone. A
mechanism that may explain the expansion of more clones carrying
the same functional defect but arising from different mutations is
selection. A theory based on this mechanism was developed for
PNH in 1989 and termed the “relative advantage,” later the “escape”
hypothesis; it is supported by several pieces of circumstantial evi-
dence, but still requires a direct confirmation. According to this
theory, a mutation in the PIG-A gene might be a fairly common phe-
nomenon, which has no biological consequences, because the
mutated cell has no chance of expanding in the presence of a vast
majority of normal cells. However, if normal hematopoiesis is inhib-
ited by a primary cause (as in idiopathic aplastic anemia [AA]), and
if the killing mechanism is directly or indirectly mediated by one or
more proteins that are GPI-linked on the surface of progenitor cells,
PIG-A mutated cells survive, undergoing clonal expansion. Because
only cells severely GPI-deficient are able to survive, in PNH serious
molecular lesions (i.e., frameshift, stop codon, and deletion) prevail
over single amino acid substitutions. Several observations indirectly
support this theory; in patients with a B-cell lymphoproliferative
disorder treated by Campath-1H (a monoclonal antibody that kills
lymphocytes targeting the GPI-linked protein CD52), severely GPI-
deficient T cells emerged; they were cloned and showed mutations
in the PIG-A gene. When a banked blood specimen that had been
drawn before monoclonal antibody treatment was searched for the
PIG-A deficient clone, a few cells carrying the same molecular
defect were detected. On Campath-1H discontinuation, the GPI-
deficient T cells gradually disappeared. Thus, this model elucidates
most features of the PNH pathogenesis: the preexistence of PIG-A
Figure 86-2 Glycosyl-phosphatidylinositol-anchor biosynthesis.
The anchor synthesis is a multistep (1–9) process that occurs in the
endoplasmic reticulum (ER), starting on the cytoplasmic side, then
flipping into the luminal side. The anchor is transferred en bloc on the
C-terminal of the protein, which is cleaved of a short sequence of
20–30 amino acids led by a signal sequence called ω. Although GPI-
deficient cell lines obtained by experimental mutagenesis have shown
defects in any step of the synthesis, all paroxysmal nocturnal hemoglo-
binuria patients studied so far are defective in the first step (⎯||→).
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Figure 86-1 (Continued) date are displayed. : small deletion or insertion and resulting in frameshift and truncated protein; : non-
sense mutation; : mutation causing altered splicing; : vast deletion; : deletion, in frame; : missense mutation. *Mutations
found in more than one patient. A small letter outside the box identifies multiple mutations found in a single patient. Only one polymorphism has
been described (55C→T, 19 arg→trp).
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demonstrated that pig-a deficient ES cells were able to differentiate
into mature cells of various hematopoietic lineages, showing that
pig-a is not necessary for differentiation and maturation of hematopoi-
etic progenitors. When tested in vivo, with chimeras obtained by
inserting pig-a knocked out ES cells during early embryonic devel-
opment, in the few surviving chimeras the proportion of GPI-defi-
cient blood cells was low at birth and decreased with aging, proving
that there is no absolute growth advantage for PNH cells as compared
with normal cells coexisting in the same organism. Mice showing in
vivo expansion of pig-a mutated hematopoiesis, thus better mimick-
ing the human PNH disease, have been obtained with a more sophis-
ticated approach. A conditional inactivation of the murine pig-a gene
was implemented using the Cre recombinase and its specific recom-
bination sites, loxP. When the Cre/loxP system was targeted to the
hematopoietic stem cells or the erythroid/megakaryocytic lineage using
tissue-specific c-FES and GATA-1 regulatory sequences, respectively,
the generation of mice having almost 100% of red cells with the PNH
phenotype was obtained. Such mice are under investigation to answer
open questions in PNH pathophysiology.
In Vitro Decreased Susceptibility of PNH Cells to Immune
Effector Mechanisms Several contradictory data have been pro-
duced on a putative differential sensitivity of normal and PNH
hematopoiesis to inhibitory stimuli. Susceptibility to apoptosis has
been reported increased, normal, or decreased in different models;
it has been shown that human cell lines carrying the PIG-A muta-
tion are less susceptible to NK-mediated killing compared with their
normal counterpart, a phenomenon that was reverted by transfection
with a PIG-A cDNA. In a more sophisticated model, GPI-deficient
mutated cells, their expansion under a selective pressure negatively
acting on normal cells by a mechanism to which the mutated cells
are resistant (for the absence of CD52), and the gradual disappear-
ance of the mutated clone once the selective mechanism has been
removed. The existence of a few (10–50 cells per million) PNH cells
in peripheral blood of healthy individuals has been documented
by analyzing cytometrically a large number of granulocytes. A
nested PCR technique confirmed the clonality of these cells by iden-
tifying the specific PIG-A mutation. The absence of an intrinsic
genomic instability in PNH patients has been shown by compari-
son with another bone marrow failure disorder, Fanconi anemia
(FA). The measurement of PIG-A spontaneous mutation rate in
B-lymphoblastoid cell lines derived from PNH or FA patients
showed a normal rate of mutation in PNH patients, contrasting with
a markedly elevated rate in FA patients. Thus, the development of
PNH cannot be attributed to increased risk of PIG-A mutations, but
only to the expansion of pre-existing rare mutant clones. The find-
ing that FA patients, although having both more PIG-A mutated
stem cells and reduced marrow cellularity, do not develop PNH,
strongly supports the escape theory: because bone marrow failure in
FA is owing to a mechanism that does not involve GPI-linked mol-
ecules, there is no growth advantage for the mutated cells.
Murine Models of PNH To explore experimentally the growth
of PNH hematopoietic stem cells, murine models have been gener-
ated. A complete knockout animal could not be produced, demon-
strating that pig-a is necessary for embryogenesis. When the mouse
pig-a gene was inactivated in embryonic stem (ES) cells with the
conventional knockout gene targeting technique, in vitro studies
Figure 86-3 GPI-linked molecules on blood cell surface. For each cell type, the molecules are listed in order of sensitivity for detecting defi-
cient cells (in bold, highest sensitivity; molecules in parenthesis, weak expression; *, also transmembrane; #, increased on cell activation; ##,
expressed only on cell activation. ^, approx 25% of early hematopoietic progenitors express CD90, which is the analog of murine Thy-1. §, in our
hands, CD59 was often present on PNH monocytes. A few molecules have been omitted that need better knowledge of their lineage-restricted
expression (ULBPs, PRV-1, PrPc, TRAIL-R3).
cells showed impairment in inducing primary and secondary stimu-
lation of both antigen-specific and alloreactive T cells, providing
experimental support for the hypothesis that the PNH clone could
inefficiently interact with the immune system. Higher apoptotic rate
of GPI+ progenitor cells compared to GPI-deficient progenitors
from the same PNH patient has been also documented. A new
family of molecules has been identified: UL16 binding proteins
(ULBPs). They are GPI-linked proteins belonging to the major his-
tocompatibility complex class I superfamily, expressed in several
tissues including immature and mature blood cells. They bind the
activating receptor NKG2D/DAP10, which is expressed on NK and
CD8+ cells, thus generating a dominant and potent stimulus for
innate and adaptive immunity; the lack of ULBPs on PNH cells may
explain the differential susceptibility to apoptosis of GPI+ and GPI–
cells, providing a rationale for escaping from immune attacks.
However, the exact mechanisms causing the escape are elusive.
They may include the absence of one or more GPI-linked molecules
directly targeted by T lymphocytes or NK cells and leading to apop-
tosis of GPI+ cells; nonspecific structural changes of the raft struc-
ture on the membrane outer surface; and impaired sensitivity to
common effector mechanisms involving GPI-linked molecules.
Evidence of an Immune-Mediated Disorder in PNH
Patients An immune attack against normal hematopoietic progen-
itors may explain marrow failure in PNH and the close boundary
with idiopathic AA, an immune-mediated disorder. Antigen-driven
immune responses are characterized by in vivo oligoclonal expan-
sion of specific T-cell subsets, which become dominant over the
residual normal repertoire. T-cell receptor analysis represents a
powerful tool for detection of clonality. In PNH, oligoclonality of
the T-cell receptor repertoire has been documented by some groups
through molecular analysis of the β-chain complementary deter-
mining region 3, by both size-distribution analysis (spectratyping or
immunoscope, Fig. 86-4) and direct sequencing of dominant
clonotypes. In some instances, a PNH clone was associated with
the presence of extremely expanded T-cell subsets, resembling
large granular lymphocyte leukemia. These observations are con-
sistent with a T-cell response involving immunodominant cyto-
toxic T-lymphocyte clones, a mechanism already advocated for
idiopathic AA; it may explain marrow failure in PNH, even if the
putative triggering antigens have not been identified.
If the escape theory is confirmed, several implications can be
drawn:
1. PNH patients always have two concomitant defects: one
(or a few) early hematopoietic progenitors carrying a PIG-A
mutation and a bone marrow failure syndrome, the mech-
anism of which is permissive for the expansion of GPI-
deficient cells. This explains the frequent association of
Table 86-2
GPI-Linked Proteins on Blood Cells and Their Function
Antigen Alternative denomination Function
CD14 LPS-LPB-r Monocyte adhesion and activation
CD16 FcγR-IIIb Low affinity receptor for IgG
CD24 Ca2+ flux, triggers H2O2 production by 
polymorphonuclear leukocytes
CD48 BLAST-1 Counter-receptor for CD2
CD52 Target of Campath-1 Unknown
CD55 DAF Accelerates C3 and C5 convertase decay,
Cromer antigen
CD58 LFA-3 Counter-receptor for CD2
CD59 MIRL Binds C8/C9, thus inhibiting MAC assembly
CD66b CGM6 (CEA family member) Granulocyte adhesion/activation
CD66c NCA Granulocyte adhesion/activation
CD73 5′-NT Purine/pyrimidine ribo/deoxyribonucleoside
phosphorylation
CD87 uPAR Urokinase receptor
CD90 Thy-1 analog Adhesion
CD108 Unknown
CD109 Platelet Gove/b alloantigen Unknown
CD157 BST-1 Enzyme; adhesion/signaling (CD38 family)
ACHE Red cell acetylcholinesterase Enzyme, unknown substrate on RBC
NAP Neutrophil alkaline phosphatase Enzyme, granulocyte function
PrPc Cellular prion protein Unknown
TRAIL R-3 Trail receptor III; DcR-1 Decoy receptor for TRAIL
ULBPs UL-16 binding proteins Activating ligand for NKG2D/DAP10 receptor
PRV-1 Polycythemia rubra vera 1 Unknown
NB1/NB2 Neutrophil antigen
JMH John Milton Hagen antigen Red cell antigen
Holley Gregory Red cell antigen
Dombrock Red cell antigen
YT Red cell antigen
Platelet GP500 Platelet antigen
Platelet GP175 Platelet antigen
LFA, leukocyte function associated; uPAR, urokinase plasminogen activator.
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detected at diagnosis (often on a banked specimen) was
present after 6–10 yr of disease course. However, addi-
tional clones may develop, as seen in a patient relapsing
after syngeneic bone marrow transplant who showed a
PIG-A mutation different from that occurring at diagnosis.
4. The aim of treatment should be to recover normal hemato-
poiesis rather than to destroy or to repair the PNH clone.
CLINICAL FEATURES
The disease is rare (prevalence approx 1–2/million), but it
occurs throughout the world, with increased prevalence in parts of
Asia (e.g., Thailand, China), in which unexplained higher inci-
dence of AA is also observed. PNH is characterized by chronic
hemolytic anemia with erratic exacerbations, frequent leukopenia
and thrombocytopenia, tendency to thrombosis, and, to a lesser
extent, to infection. The clinical picture can range from mild to
severe, severity being dictated by extreme pancytopenia (the
PNH/AA syndrome), hyperhemolysis, or recurrent thrombosis.
PNH with AA, the increased incidence of PNH in coun-
tries where AA is more frequent, as well as the frequent
association of both diseases with human leukocyte anti-
gens known to be related to autoimmune disorders.
2. The PNH clones, although responsible for a number of
clinical consequences, are not invasive; rather, they should
be considered “salvage” clones, which positively mitigate
the consequence of bone marrow failure. Indeed, the gene
expression profile of CD34+ PNH cells as studied by a
microarray technique is similar to that of CD34+ cells
from normal individuals, whereas phenotypically normal
CD34+ cells sorted from PNH patients showed overex-
pression of genes possibly related to immune-mediated
damage, such as TRAIL, interferon-γ, p53, and caspase 3,
as seen in AA patients.
3. The long survival of patients with PNH demonstrates that
a single stem cell may support most of hematopoiesis for
several years. The same single PIG-A gene mutation
Figure 86-4 T-cell repertoire by TCR-VB CDR3 size-distribution analysis (immunoscope) in paroxysmal nocturnal hemoglobinuria (PNH)
patients. The complementary determining region 3 (CDR3) mRNA pool is amplified by reverse transcriptase-PCR using a fluorescent constant-B
primer and the specific variable-B (VB) primer. The complexity of the VB-CDR3 repertoire is resolved on acrylamide gel and displayed as rela-
tive fluorescence intensity (vertical axis): peaks represent mRNAs of identical length (horizontal axis). In healthy individuals, the normally diverse
repertoire consists of 6–10 peaks, 3 nucleotides distanced from each other (representing in-frame functional rearrangements), with a bell-shaped
(Gaussian like) distribution. In PNH, T-cell oligoclonality results in the appearance of prominent peaks out of the bell (skewing); in this paradig-
matic PNH patient, VB3, VB7, VB9, VB14, VB16, VB20, VB21, and VB24 are skewed. (Reproduced with permission from Karadimitris A,
Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal noc-
turnal hemoglobinuria. Blood 2000;96:2613–2620. © American Society of Hematology.)
Although the disease is not malignant (progression to acute
leukemia is rare, and the frequency may have been overestimated),
with a median survival of 10 yr in large series, the course may be
stormy and the quality of life poor. The major cause of death is
thrombosis, often occurring in sites unusual for patients with other
types of thrombophilia (suprahepatic veins leading to Budd-Chiari
Figure 86-5 Blood cell flow cytometry profile in a representative paroxysmal nocturnal hemoglobinuria patient. (Upper panels): ungated red
cells stained with anti-CD59 monoclonal antibody (mAb), showing three RBC populations, one normal, a second partially CD59 deficient (PNH II)
and a third, completely CD59 deficient (PNH III). (Middle left panel): WBC are gated into three discrete populations by the combination of anti-
CD45 and anti-CD33 mAbs. Granulocytes, stained with an anti-CD66b mAb, show two well-cut populations, one normal, and the other CD66b
deficient; monocytes, stained with an anti-CD14 mAb, show a major population completely CD14 deficient and two smaller populations (one par-
tially deficient and few normal cells); lymphocytes stained with an anti-CD48 mAb show a single peak of positive cells.
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patients or from matched unrelated donors in young patients carry
a high transplant-related mortality, which can be tolerated only if
the quality of life of the patient is poor. If the escape theory is cor-
rect, there is little room for futuristic approaches with cell therapy
(insertion of molecules on the outer surface of blood cells) or with
gene therapy (insertion of a functional PIG-A gene in early
hematopoietic progenitors) in PNH, because a repair of the dam-
aged cell may result in cell destruction. In most PNH patients, a
residual population of normal hematopoietic progenitors already
exists, but it is unable to repopulate bone marrow.
A supportive treatment has been envisaged by using a mono-
clonal antibody targeting the fraction C5 of the complement cascade
eculizumab; by blocking the formation of the terminal membrane
attack complex, both chronic and paroxysmal hemolysis can be
reduced, with favorable clinical consequences at least concerning
hyperhemolysis (decreased lactate dehydrogenase, reduced transfu-
sion requirement), even if the PNH population remains unchanged
or even increases.
FUTURE DIRECTIONS
Although many pathophysiological aspects of PNH have been
unraveled, several important items require clarification, such as:
1. The functional properties of the GPI-anchoring system in
human cells.
2. The structure and the function of the protein encoded by
PIG-A.
3. The exact role of each GPI-linked molecule on blood cell
development and function.
4. The amount of transfer of GPI-linked molecules that may
take place in vivo from one cell to another.
5. The hierarchy by which the various molecules are preferred
in the cell for anchor attachment, when a reduced amount
of anchor is produced.
6. The reason for the nocturnal exacerbation of hemolysis.
Also, a formal proof of the escape theory is needed. If confirmed,
PNH could be regarded as a special type of nonneoplastic clonal
disease, in which the expansion of the mutated cell results from a
survival advantage rather than a growth advantage.
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